Zanamivir

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

A sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles selectively inhibits the growth of influenza A and B viruses in plaque reduction assays (IC₅₀s = 5-14 nM) and to directly inhibit

A sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles selectively inhibits the growth of influenza A and B viruses in plaque reduction assays (IC₅₀s = 5-14 nM) and to directly inhibit

A sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles selectively inhibits the growth of influenza A and B viruses in plaque reduction assays (IC₅₀s = 5-14 nM) and to directly inhibit

A sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles selectively inhibits the growth of influenza A and B viruses in plaque reduction assays (IC₅₀s = 5-14 nM) and to directly inhibit